Clinical Trial Update: Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

View source ↗

Summary

This document presents a meta-analysis of post-marketing surveillance data evaluating SGLT2 inhibitors in patients with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)
• Dapagliflozin (dapagliflozin)
• Empagliflozin (empagliflozin)
• Ertugliflozin (ertugliflozin)

Snippet

Sponsor: Pharmaceuticals and Medical Devices Agency, Japan | Conditions: Diabetes Mellitus, Type 2 | Status: UNKNOWN